Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ATNM |
---|---|---|
09:32 ET | 6531 | 7.88 |
09:34 ET | 100 | 7.9365 |
09:36 ET | 464 | 7.8572 |
09:38 ET | 1100 | 7.9299 |
09:41 ET | 3485 | 7.895 |
09:43 ET | 1720 | 7.88 |
09:45 ET | 11965 | 7.8 |
09:48 ET | 2074 | 7.8193 |
09:50 ET | 5320 | 7.785 |
09:52 ET | 2013 | 7.7524 |
09:54 ET | 1100 | 7.83 |
09:56 ET | 100 | 7.825 |
09:57 ET | 1010 | 7.85 |
10:01 ET | 200 | 7.845 |
10:03 ET | 100 | 7.87 |
10:06 ET | 3000 | 7.8699 |
10:08 ET | 800 | 7.8988 |
10:10 ET | 350 | 7.8731 |
10:12 ET | 100 | 7.9 |
10:14 ET | 949 | 7.85 |
10:15 ET | 300 | 7.87 |
10:17 ET | 100 | 7.86 |
10:19 ET | 1596 | 7.8 |
10:24 ET | 199 | 7.745 |
10:26 ET | 100 | 7.71 |
10:28 ET | 2734 | 7.785 |
10:30 ET | 400 | 7.78 |
10:32 ET | 364 | 7.775 |
10:35 ET | 2381 | 7.79 |
10:37 ET | 200 | 7.79 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Actinium Pharmaceuticals Inc | 234.4M | -4.5x | --- |
Omeros Corp | 237.0M | -1.4x | --- |
Tenaya Therapeutics Inc | 248.1M | -1.9x | --- |
Inovio Pharmaceuticals Inc | 221.8M | -1.5x | --- |
Aldeyra Therapeutics Inc | 215.7M | -7.0x | --- |
Monte Rosa Therapeutics Inc | 215.4M | -1.4x | --- |
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $234.4M |
---|---|
Revenue (TTM) | $81.0K |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.21 |
EPS | $-1.72 |
Book Value | $1.32 |
P/E Ratio | -4.5x |
Price/Sales (TTM) | 2,893.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -61,645.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.